Drugmaker Cipla has received regulatory approval in India to sell its version of Truvada as a preventive that can be given to healthy people to reduce their risk of getting HIV.
Commonly referred to as PrEP (pre-exposure prophylaxis) in healthcare circles, Truvada, sold by US drugmaker Gilead, is the only medicine globally approved as a preventive in managing HIV. And the recent approval in India as a preventive marks a significant step in HIV prevention efforts, especially in couples where one partner is HIV positive. Confirming the development, Cipla’s Medical Director Jaideep Gogtay told .Cipla is the first company to get an approval from the Drug Controller General of India (DCGI) to sell its version of the drug (Tenvir EM) as a preventive. The drug has been in use in India for about eight years now, but only for the treatment of people with the HIV infection, he said. The big difference now is that it is used to prevent infection in healthy people.